Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12

Journal of Immunotherapy

Volumn 27, Issue 6, 2004, Pages 452-459

  Kikuchi, Tetsuro ^a,b,f   Akasaki, Yasuharu ^b   Abe, Toshiaki ^b   Fukuda, Takahiro ^b   Saotome, Hideo ^c   Ryan, John L ^d   Kufe, Donald W ^e   Ohno, Tsuneya ^a  

^a Institute of DNA Medicine   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c AHP Services Japan Co Ltd   (Japan)

^d PFIZER INC   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NONE   (Japan)

Author keywords

Brain tumor; Dendritic cells; Glioma; Immunotherapy; Interleukin 12

Indexed keywords

MACROGOL; RECOMBINANT INTERLEUKIN 12;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL FUSION; CONTROLLED STUDY; CONVULSION; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; LEUKOPENIA; LIVER DYSFUNCTION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TUMOR VOLUME; VACCINATION;

EID: 7444220033     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200411000-00005     Document Type: Article

References (17)

1. Brandes A, Soesan M, Fiorentino MV. Medical treatment of high grade malignant gliomas in adults: an overview. Anticancer Res. 1991;11:719-727.
2. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296.
3. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
4. Reeves ME, Royal RE, Lam JS, et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 1996;56:5672-5677.
5. Nair SK, Snyder D, Rouse BT, et al. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer. 1997;70:706-715.
6. Tjandrawan T, Martin DM, Maeurer MJ, et al. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother. 1998;21:149-157.
7. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996;183:87-97.
8. Tuting T, Wilson CC, Martin DM, et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol. 1998;160:1139-1147.
9. Celluzzi CM, Falo LD. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol. 1998;160:3081-3085.
10. Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3:558-561.
11. Akasaki Y, Kikuchi T, Homma S, et al. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother. 2001;24:106-113.
12. Wang J, Saffold S, Cao X, et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol. 1998;161:5516-5524.
13. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. 2001;50:337-344.
14. Brunda M. Interleukin-12. J Leukoc Biol. 1994;55:280-288.
15. Aoki T, Tashiro K, Miyatake S, et al. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA. 1992;89:3850-3854.
16. Wakimoto H, Abe J, Tsunoda R, et al. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res. 1996;56:1828-1833.
17. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12- associated toxicity and interferon-gamma production. Blood. 1997;90:2541-2548.